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Case presentation
Patient 1. A 44-year-old man was evaluated as a potential renal
transplant donor for his sister, He had been in good health except for
upper gastrointestinal bleeding 4 years previously. At that time, endos-
copy demonstrated gastritis and a duodenal ulcer; he was treated with
ranitidine for 3 months, and the symptoms did not recur. He was an
alcoholic, but he had not used alcohol in more than 5 years; he attended
Alcoholic Anonymous meetings regularly and he was employed full-
time as a truck driver. He had no known allergies.
Physical examination in the Nephrology Clinic at New England
Medical Center (NEMC) disclosed: weight, 100.6 kg; blood pressure,
110/80mm Hg; pulse, 68 beats/mm. Laboratory examination was within
normal limits: hemoglobin, 14.0 mg/dl; creatinine, 0.8 mg/dl; and
normal liver enzymes. Urinalysis revealed a specific gravity of 1.030;
pH, 6.0; trace protein; and negative heme. The urine sediment con-
tained 0—5 epithelial cells, no red blood cells, and an occasional white
blood cell/high-power field. He was eager to become a transplant donor,
and he was referred to a urologist and a social worker for further
evaluation.
Repeat urinalysis by a urologist revealed a specific gravity of 1.014;
2+ heme; and trace protein. Microscopic examination showed 5—10 red
blood cells and 0—1 white blood cells/high-power field and no casts.
Intravenous pyelogram and cystoscopy were normal, and neither
indicated the source of the hematuria. The patient returned to the
Nephrology Clinic, and repeat urinalysis on two separate occasions
demonstrated no hematuria. Review of his record from another hospital
revealed that he had had trace to 1 + hematuria on dipstick examination
when hospitalized for peptic ulcer disease.
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After extensive discussion with the patient, a renal biopsy was
performed to determine whether a renal source of the hematuria could
be identified. The biopsy demonstrated mild mesangial expansion on
light microscopy; immunofluorescence microscopy showed IgA depos-
its in a focal distribution in all glomeruli. Because of this information, he
did not donate a kidney to his sister.
Patient 2. A 47-year-old woman with systemic lupus erythematosus
was admitted to the NEMC for renal biopsy. The initial clinical
manifestations of lupus occurred 30 years previously in the form of
thrombocytopenic purpura and proteinuria. Thrombocytopenia im-
proved with high-dose prednisone therapy, but proteinuria (200—600
mg/24 hr) persisted. The serum creatinine was less than 1.0 mg/dl on
numerous occasions. Fifteen years ago, she developed Sjogren's syn-
drome but was otherwise asymptomatic. At that time, the 24-hour
urinary protein excretion was 6.2 g, the BUN was 9 mg/dl, and the
serum creatinine was 0.6 mg/dl. Urinalysis disclosed: specific gravity,
1.014; 3+ heme; 4+ protein; and many red blood cells with occasional
granular casts. An LE prep was positive. The Sjogren's syndrome was
treated symptomatically.
Eight years prior to admission, she developed cutaneous vasculitis of
the arms and legs, bilateral pulmonary infiltrates, and anemia. The
serum creatinine was 1.0 mg/dl, the BUN was 15 mg/dl, and an
anti-nuclear antibody titer was 1:65,000. Urinary protein excretion was
700 mg/24 hours. An open lung biopsy revealed pulmonary hemosidero-
sis; renal biopsy showed membranous nephropathy with mild mesangial
proliferation. Prednisone was administered (60 mg/day). Hypertension
required therapy with cionidine and hydrochlorothiazide. The pred-
nisone was slowly tapered over the next 2 years, she became normoten-
sive, and all of the extrarenal manifestations of lupus resolved.
Four years prior to admission, the patient had another flare of lupus
erythematosus characterized by lymphadenopathy, splenomegaly, pul-
monary infiltrates, and anemia. At that time, her blood pressure was
normal, serum creatinine was 0.8 mg/dl, and 24-hour urinary protein
excretion was 1.4 g. Renewed therapy with 60 mg of prednisone daily
resolved the extrarenal disease activity. The prednisone was slowly
tapered over the next year; extrarenal manifestations did not recur.
Over the past 18 months, the patient has had pedal edema for the first
time, and she has gained 12 pounds. Her blood pressure became
elevated, and furosemide was administered. She was referred to NEMC
for further evaluation. Other than the edema, she had no acute
complaints. Physical examination revealed: blood pressure, 120/80 mm
Hg; pulse, 88 beats/mm; and 2+ pedal edema. The rest of the exami-
nation was normal. Urinalysis disclosed a specific gravity of 1.015; 4+
protein; and pH, 5.5. Microscopic examination of the urine revealed 0—2
white blood cells, 0—3 red blood cells, occasional granular casts, and
many oval fat bodies; urinary protein excretion was 5.3 g/24 hr. The
serum creatinine was 1.2 mg/dl; serum albumin, 2.2 g/dl; anti-dsDNA
antibody level, 3.8 mg/dl; CH50, 168 U (normal, 150—200 U); C3, 0.85
mg/mi (normal, 0.87—2.20 mg/mI); and C4, 0.17 mg/mI (normal, 0.15—
0.54mg/mi). Renal biopsy demonstrated membranous glomerulonephri-
tis with segmental glomerulosclerosis and interstitial fibrosis, consistent
with class-V lupus nephritis.
Patient 3. A 23-year-old man who previously had been in excellent
health presented to the emergency ward of a local hospital with a 2-day
history of nausea, vomiting, chills, and myalgias, and a one-day history
of bilateral flank aching and dark urine. He had no history of hematuria,
renal disease, hypertension, diabetes, or substance abuse, nor had he
had recent symptoms of an upper respiratory or gastrointestinal illness.
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At the onset of symptoms, he had been attending an engineering
conference on Cape Cod.
On examination his blood pressure was 130/70 mm Hg and the pulse
was 76 beats/mm. He had mild flank tenderness and no edema. The
examination was otherwise nOrmal. Urinalysis disclosed: specific grav-
ity, 1.012; pH, 5; 3+ protein; 4+ heme; and no glucose. The urine
sediment contained 20—30 red blood cells. 4—5 renal tubular epithelial
cells, and no casts or crystals. The hematocrit was 44%, white blood
cell count, 18,000/mm3 with a normal differential; platelet count,
277,000/mm3; BUN, 31 mg/dl; and serum creatinine, 6.7 mgldl. Serum
electrolytes were: sodium, 139 mEq/liter; potassium, 4.6 mEq/liter;
chloride, 110 mEq/liter; bicarbonate, 24 mM/liter; albumin, 3.8 gldl;
calcium, 5.5 mg/dl; phosphorus, 6 mg/dl; and creatine phosphokinase,
1141 U/liter. A renal ultrasound examination demonstrated no hydro-
nephrosis; the left kidney was 12.3 cm and the right kidney 11.9 cm in
length. A renal scan showed blood flow bilaterally but diminished
excretion.
On further questioning the patient reported that 2 days previously,
while walking along the beach, he became thirsty and drank from a
rinsed jug that previously had contained antifreeze. A serum osmolality
was measured at 299 mOsm/liter. The serum also was evaluated for
ethanol, methanol, and ethylene glycol, but they were not found. He
underwent emergency hemodialysis for possible ethylene glycol poison-
ing, and he received 1 g of methyiprednisolone on 3 successive days as
therapy for possible rapidly progressive glomerulonephritis.
Five days after the onset of symptoms, he was transferred to NEMC.
On admission his physical examination was unremarkable; blood pres-
sure was 120/80 mm Hg. Laboratory studies revealed: BUN, 71 mg/dl;
serum creatinine, 12.2 mg/dl; hematocrit, 38%; and creatine phosphoki-
nase, 866 U/liter. Urinalysis disclosed: specific gravity, 1.016; pH, 5;
3+ protein, 3+ heme; 10—20 white blood cells, 100 red blood cells, and
0—3 granular casts/high-power field. Renal biopsy demonstrated acute
tubular necrosis with many calcium oxalate crystals in the interstitium.
The patient underwent three additional hemodialysis treatments, and
his renal function gradually improved. Three months later the patient's
serum creatinine was 1.0 mgldl, and his urinalysis and sediment were
normal.
Discussion
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center, and Associate Professor of Medicine,
Tufts University School of Medicine, Boston, Massachusetts):
The use and interpretation of the renal biopsy evoke strong
opinions and confrontations among even the most docile ne-
phrologists [11. The decision to biopsy the kidney raises many
issues, including indications and contraindications, optimal
timing, choice of technique, complications, interpretation of the
material, and utilization of information. Several textbooks are
devoted to various aspects of these issues [2—5]. In this Forum,
I will confine my remarks to problems that the nephrologist
commonly encounters in routine practice. I will discuss se-
lected technical and clinical aspects of the renal biopsy proce-
dure and the informational content of the biopsy. I also will
consider indications for renal biopsy in patients with several
major renal syndromes, including isolated hematuria, mild to
moderate proteinuria, nephrotic syndrome, glomerulonephritis,
acute renal failure, and chronic renal failure. I will not discuss
the use of renal biopsy in renal transplantation, in pregnant
women, or in children. In addition, I will not consider the
histologic interpretation of biopsy specimens in various disease
states.
The first renal biopsies, reported in 1923, were open surgical
procedures [6]. Ball described the first percutaneous needle
biopsy in 1934 [7]. In 1943 Castleman and Smithwick system-
atically evaluated 100 surgical biopsies of hypertensive patients
and commented, "Pathologists are so accustomed to the micro-
scopic appearance of the hypertensive kidney from autopsy
material with the usual postmortem changes, that at the begin-
ning of this study some of the findings due to the early fixation
(a matter of seconds) seemed so conspicious that they were at
first believed to be pathologic" [8].
The percutaneous approach became routine after 1950 with
the reports of Perez-Ara [9], Iverson and Brun [10], and Alwall
[11]. In 1954 Kark and Muehrcke modified the procedure by
positioning the patient in the prone rather than in the upright
position, using an exploring needle to localize the kidney prior
to the insertion of a biopsy needle, and utilizing the Franklin-
modified Vim-Silverman needle [12]. These modifications re-
sulted in a greater likelihood of procurement of tissue and a
larger core of tissue for microscopic evaluation. Since these
initial reports, technical innovations principally have focused
around more accurate localization of the kidney prior to biopsy
and on immediate microscopic inspection of the tissue ob-
tained. I will discuss these aspects in a moment, but before
proceeding I would like to consider the circumstances in which
percutaneous renal biopsies generally have been considered
'contraindicated."
Contra indications
A major contraindication to performing percutaneous renal
biopsy is a bleeding diathesis. In most circumstances, the
bleeding disorder can be corrected prior to and for a few days
after the biopsy. If the disorder cannot be corrected and the
biopsy is deemed indispensable, an open surgical biopsy should
be considered because the site can be visualized directly and
bleeding can be controlled locally [13, 14]. Open biopsy can be
performed with the patient under general or local anesthesia.
Chodak and colleagues utilized mild sedation, local anesthesia,
and direct visualization in 123 high-risk patients [14], including
patients with bleeding abnormalities (37), uncontrolled hyper-
tension (26), anatomic abnormalities (19), previous technical
failure (19), uncooperative behavior (13), pregnancy (5), and
unspecified conditions (21). Adequate tissue was obtained in all
patients (mean number of glomeruli = 54). Complications were
observed in 6 patients: 3 had wound hematomas, 2 had wound
infections, and one required surgery for repair of a colocutane-
ous fistula; no deaths were reported.
Transvenous renal biopsy may be another alternative in
high-risk patients. In a preliminary report, Mal and coworkers
performed renal biopsies through the internal jugular vein using
a 9 F catheter with a 66 cm needle under vacuum aspiration in
36 patients [15]. Of the 36, 12 had a severe clotting disorder, 4
had chronic respiratory failure, 2 had uncontrolled hyperten-
sion, 12 needed a liver and kidney biopsy, and conventional
biopsy failed in 6. Adequate tissue (mean number of glomeruli
SD = 9.5 5) was obtained in 25 of the 36, and the
complications were minor (macroscopic hematuria in 3 pa-
tients, hematoma in 2). Until more experience accumulates, and
a better yield of tissue is obtained, however, the modified open
procedure described here seems more prudent in high-risk
patients.
A second major contraindication to percutaneous renal bi-
opsy is the inability of a patient to comply with instructions.
Mild sedation often improves compliance in children [16, 17].
On rare occasions, general anesthesia is necessary to obtain
renal tissue in the patient who cannot cooperate. When per-
Nephrology Forum: Renal biopsy 531
forming an open biopsy under general anesthesia, a core or cup
of tissue should be obtained with a needle or forceps. Wedge
resection should be avoided, because it can yield inappropriate
material for histologic examination [14]. For example, if an area
of fibrosis is biopsied, it might not provide diagnostic informa-
tion.
Severe hypertension or hypotension, renal abscesses, pyelo-
nephritis, hydronephrosis, severe anemia, uremia, large renal
tumors, and cysts are relative contraindications to renal biopsy
[18, 19]. However, if blood pressure is restored to normal, if
urinary infection or obstruction is eradicated prior to the
procedure, and if uremia or severe anemia is corrected, biopsy
can be carried out safely [19—22].
Some nephrologists have argued that patients with only a
single functioning kidney should not be subjected to percutane-
ous biopsy, and that if the biopsy must be done, it should be an
open biopsy under direct visualization [18, 19, 23]. I think these
beliefs require reevaluation. Let us begin by examining the risk
of nephrectomy after renal biopsy. Using data from a question-
naire, Welt performed a respective analysis and reported at the
first meeting of the American Society of Nephrology that only 5
of 8081 patients who were biopsied (1/1616) required a nephrec-
tomy [24]. Other investigators have estimated the incidence to
be 1/2000 to 1/5000 [18, 19, 21, 23]. The risk of death from
general anesthesia, which may be required for an open biopsy,
is available for comparison and varies with the American
Society of Anesthesia (ASA) physical status class. The ASA
physical status categories range from class 1 (no physiologic or
pyschologic disturbance) to class 5 (the moribund patient who
has minimal chance for survival). For class-2 patients (mild to
moderate systemic disturbances, that is, essential hyperten-
sion, mild diabetes, or anemia), the death rate is 3/1000 [25—28].
For patients with more severe disorders, the mortality rate
specifically attributed to general anesthesia is higher; it is 1.8%
for class-3 patients and 7.8% for class-4 patients [25—28]. In
most situations, therefore, the risk of death from general
anesthesia is comparable to the risk of nephrectomy following
closed biopsy. All patients, including those with two kidneys,
are exposed to a similar risk from anesthesia. Furthermore,
biopsies of transplanted kidneys are performed routinely with
excellent results and without important complications [29]. I do
not believe, therefore, that a solitary kidney is an absolute
contraindication to renal biopsy. In patients at higher risk for
bleeding complications (those with small kidneys, uremia,
bleeding diathesis), an open procedure under local anesthesia
sometimes is more prudent, however.
In my opinion, special caution should be used in the biopsy of
patients with chronic renal disease and small kidneys (end-stage
renal disease). The risk of serious complications is substantially
increased in this group [13, 18, 19, 30, 31]. Kropp et al reported
that 5 of 29 patients (17%) with end-stage renal failure who
underwent percutaneous biopsy experienced significant compli-
cations [30]. Similar observations have been reported by others
[31], and most authors report an increased incidence of bleeding
[19, 21, 23]. Of course, chronic renal insufficiency is not
equivalent to end-stage renal failure. Renal biopsy appears to be
relatively safe (that is, it produces no apparent increase in major
complications) in patients with a gradual, progressive decline in
GFR (as opposed to acute renal failure) and a serum creatinine
greater than 2.0 mg/dl, provided that the kidneys are not
reduced in size [20—22]. Most biopsy series of patients with
chronic renal failure have had relatively small numbers of
patients, however, and these results must be viewed with
caution. Furthermore, although renal biopsy establishes a diag-
nosis in the majority of such patients, the likelihood of obtaining
information that will affect future therapy is minimal. Therefore
a renal biopsy in these patients is warranted only infrequently.
Procurement of tissue
In their initial report in 1951, Iverson and Brun described
localization of the lower pole of the right kidney using intrave-
nous pyelography and a lead mark on the skin [10]. Neverthe-
less, many large series of renal biopsies report a high degree of
success using the "blind" technique based on anatomic land-
marks as described by Kark and Muehrcke in 1954 [12].
According to Welt's questionnaire, 6393 renal biopsies had
been performed by the "blind" technique, compared with 1398
done under guidance of image-intensification fluoroscopy [24].
Over 90% of procedures performed by either method yielded
renal tissue. A 95% success rate (5 or more glomeruli) was
reported by Diaz-Buxo and Donadio in 1000 patients; 176
procedures were performed under fluoroscopic guidance, and
the rest were performed by the "blind" technique [21]. Most
biopsies today are performed using one of a variety of tech-
niques for localization of the kidney, including image amplifi-
cation fluoroscopy [32, 33], radionuclide scan [34, 35], retro-
grade pyelography [36], ultrasound [37], and computerized
tomography [38]. Despite the large variety of imaging proce-
dures for visualizing the kidney during biopsy, only a few
reports have compared the adequacy of samples using these
procedures. Most of these studies provide limited information
because of the small number of patients included. In a study of
48 patients, Bolton and coworkers compared radionuclide scan,
intravenous pyelography, and ultrasonography to image-ampli-
fication fluoroscopy, regarded by these authors as the standard
[37]. Radionuclide scan correlated best with fluoroscopically
determined kidney length (9.9 0.2 cm versus 9.6 0.2 cm, P
= NS) and width (5.7 0.2 versus 5.8 0.2, P = NS), whereas
the kidney appeared significantly larger by ultrasound (length,
10.8 0.3, P < 0.5; width, 6.2 0.2, P = NS) and by
pyelogram (length, 13.8 0.3, P < 0.001; width, 7.2 0.2, P <
0.001) (as compared with fluoroscopy). Ultrasound localized
the lower pole most accurately, and it correlated best with the
fluoroscopically determined depth of the kidney. The kidney
could be localized in all patients by ultrasound, but renal
dysfunction limited localization in 10 patients by scan, 5 pa-
tients by intravenous pyelogram, and 4 patients by fluoroscopy.
The complication rate among the different methods has not
been evaluated systematically. More recently Birnholz et al
described an ultrasound guidance technique using a probe
positioned along the mid-axillary line [39]. As the biopsy needle
is advanced, its route is monitored by continuous ultrasound
guidance. Using this technique, they obtained renal tissue in 29
of 31 patients; after some practice, they could perform the
entire procedure within 20 minutes. Similar results have been
reported by others [40]. However, the procedure has not been
systematically compared with the other techniques I described.
A further modification of the ultrasound guidance technique
is the utilization of an automated biopsy instrument [41]. This
spring-loaded device, containing an 18 gauge biopsy needle (17
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mm specimen notch), is passed through a guide on a transducer
to the capsule. The authors state: "Activation causes the
obdurator to advance 23 mm into the kidney followed immedi-
ately by the cannula" [41]. The actual time the biopsy needle is
within the kidney is reduced. Furthermore, the procurement of
tissue requires less dexterity compared with use of the Tru Cut
or Franklin modified Vim-Silverman needle. Whether or not
these modifications will result in a reduction in the rate of
serious complications, however, has not been evaluated.
My preference is to use ultrasound to localize the kidney,
because it does not require radiocontrast material, and the
kidney usually can be localized even if the patient has renal
insufficiency. From the limited data available, the yield of renal
tissue obtained using ultrasound is at least comparable to that
obtained with other methods. An experienced ultrasound tech-
nician is an essential member of the biopsy team. I find it useful
for the technician to outline the lower pole of the kidney and the
precise point of entry on the surface of the skin and to provide
advice regarding the orientation of the needle.
The procedure described by Kark and Muehrcke in 1954 for
procurement of tissue is remarkably similar to that used today,
and I refer the reader to the original text for this description
[12]. 1 prefer the disposable Tru Cut needle (Travenol Labora-
tories, Deerfield, IL) to the Vim-Silverman needle described by
Kark [42]. Usually it provides adequate cores with minimal
distortion of tissue, and the cutting edge does not need to be
sharpened.
Following the procedure, the patient should assume the
supine position for the next 12 to 24 hours and should undergo
frequent assessment of vital signs. During this interval, fluids
should be administered liberally (assuming renal function is
adequate), and the color of the urine should be monitored. I
usually obtain a hematocnt on the following morning, unless the
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Fig. 2. Binomial distributions of the number of abnormal glomeruli
which would be found in biopsy samples obtained from kidneys with an
actual percentage of abnormal glomeruli of 10, 35, and 50%. Biopsies
containing 10 giomeruli (A) and 20 glomeruli (B) are shown. The
horizontal axis is the number of abnormal glomeruli seen in the biopsy,
and the vertical axis is the probability of having exactly that number of
abnormal glomeruli. (From Ref. 44.)
vital signs change before then. Gross,hematuria usually clears
promptly; if so, the patient can be discharged from the hospital
the day after the biopsy. The patient should be instructed to
avoid heavy physical exertion for the next few weeks.
Characteristics of the sample
The features of the tissue sample that influence the accuracy
of diagnosis and prognosis, and consequently the appropriate-
ness of therapeutic approaches, have been analyzed by Thom-
sen [43] and by Corwin et al [44]. Let us use the diagnosis of a
focal glomerular lesion to illustrate these concepts. First, con-
sider the recognition of focal diseases. For the diagnosis of a
focal disease, such as focal segmental glomerular sclerosis, the
finding of a single abnormal glomerulus establishes the diagno-
sis. However the probability that focal sclerosis is not present
in a patient (that is, someone with idiopathic nephrotic syn-
drome) depends both on the actual fraction of abnormal gb-
meruli and on the number of glomeruli obtained in the biopsy
specimen. This point is illustrated in Figure 1 [43]. IfS gbomeruli
are present in the biopsy specimen, and the actual glomerular
involvement is 20%, there is a 35% chance that all glomeruli in
the biopsy specimen will be normal. By contrast, if the actual
glomerular involvement is 20% and 10 glomeruli are obtained,
.60
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Involvement in kidney
10% 35% 50%
I I I
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A
Number of abnormal glomeruli
in biopsy of 10 glomeruli
9 10
Fig. I. Probability of finding only normal glomeruli in a biopsy speci-
men of n glomeruli, when the true relative frequency of normal
glomeruli in the kidney is known, Graphic presentation for varying
values of n. (With permission, from: A. C. Thomsen: The Kidney in
Diabetes Mellitus, Munksgaard, Copenhagen, 1965).
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Fig. 3. Binomial distribution of percentage of abnormal glomeruli in
biopsy samples from kidneys with mild (10%), moderate (35%), and
severe (60%) involvement, (From Ref. 44.)
the chance of finding all normal glomeruli is only 10%. If,
however, the actual percentage of involvement is only 10% and
10 glomeruli are sampled, the probability of finding all normal
glomeruli is 88%.
Next consider how sampling influences our assessment of the
proportion of glomenilar involvement, again in a patient with a
focal glomerular lesion. Unless all glomeruli within the kidney
are abnormal and affected equally, the number of abnormal
glomeruli in a given biopsy specimen will vary. The probability
that the observed involvement accurately predicts actual in-
volvement is related to both the number of glomeruli in the
specimen and the actual fraction of glomeruli affected [44].
(This probability is based on the assumption that the disease is
randomly distributed throughout the kidney and the specimen).
This principle has a number of practical implications (Figs.
2—5). If a biopsy containing 10 glomeruli discloses 3 abnormal
glomeruli, the probability that 30% of glomeruli are actually
abnormal is approximately 25%. There is a 10% chance that the
actual involvement is 50%, and a 5% chance that the involve-
ment is only 10% (Fig. 2A). If, however, the sample contains 20
glomeruli with 6 abnormal glomeruli (Fig. 2B), the probability
of either 10% or 50% involvement is reduced to less than 5%.
The probability that the glomerular involvement is within a
given range (confidence interval) also can be derived from the
number of glomeruli in the biopsy and the percentage of
involvement (Fig. 3). For example, in a biopsy with 10 glomer-
uli and 30% involvement, there is a 95% probability that actual
glomerular involvement is between 7% and 65%. With 30
glomeruli and 30% actual involvement, the 95% confidence
interval is reduced to 15% to 50%. Based on these principles,
Table 1. Minimum number of abnormal glomeruli that must be
present in a biopsy containing a certain number of glomeruli to infer
with 95% confidence that the disease process involves 80%, 50%, or
20% of the kidneya
Total number
of glomeruli
in biopsy
Extent of disease involvement in the kidney
80%b 50%b 20%b
8 8 (100)" 7 (88) 3 (38)
10 10(100) 8(80) 4(40)
12 12 (100) 9 (75) 5 (42)
15 14(93) 11(73) 6(40)
20 19 (95) 14 (70) 7 (35)
25 23 (92) 17 (68) 9 (36)
30 28 (93) 20 (66) 10 (33)
35 32(91) 23(66) 11(31)
40 36 (90) 26 (65) 12 (30)
a p = 0.05 (one tailed). (From Ref. 44.)b Percentage of involvement in the kidney sought.
Figures in parentheses are percentages of abnormal glomeruli in a
biopsy.
the minimum number of glomeruli necessary to confidently
assume a given level of involvement can be calculated (Table 1).
Sampling issues are especially important in the design of
clinical trials. If 50% glomerular involvement is an entry crite-
rion for a study, for example, the glomerular involvement
should be based on the sample size to assure that all patients
meet this requirement. Meeting the 50% cutoff criterion would
require that 7 glomeruli are involved in a specimen containing 8
glomeruli. With larger samples, of course, the required percent-
age of involvement is less. Thus, to assure a given level of
involvement with confidence (that is, 95%), the requirements
should vary depending on the number of glomeruli in the
specimen.
These concepts have additional strategic implications for
study design. When classifying patients into disease categories,
the number of patients with inappropriate assignments should
be considered. Corwin et al give the example of patients with
systemic lupus erythematosus (Fig. 4) [44]. Distinctions that
rely on small differences in the percentage of abnormal glomer-
uli (that is, mild versus moderate, or moderate versus severe
involvement) have little meaning because there is a large
overlap among patient groups. To assign patients accurately to
either mild or moderate disease categories, more than 100
glomeruli per specimen are required! Given that the usual
number of glomeruli per specimen usually is substantially less
than this, a distinction based on greater differences in the
groups would be much more meaningful (that is, <20% versus
>50% involvement).
One should assess whether adequate tissue has been obtained
during the procedure itself. A decision whether to obtain more
tissue should be based on an estimate of the number of
glomeruli obtained and on the nature of the disease process(es)
suspected. At least two cores of tissue are obtained for routine
pathologic examination. Each specimen should be examined
directly by light microscopy with tenfold magnification for the
presence of glomeruli [42], and the number of glomeruli should
be estimated. Using this procedure, one can obtain adequate
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Fig. 4. Classification of patients into mild, moderate, or severe disease
on the basis of biopsy sample (y-axis) as prevalence of abnormal
glomeruli in kidney is varied (x-axis). Misclassification into greater
severity is indicated by gray area and lower severity by hatched mark
area. (From Ref. 44.)
tissue for pathologic examination in 90% to 95% of patients.
Needless to say, the condition of the patient also is a critical
determinant: if the patient is unable or unwilling to continue,
the procedure must be stopped.
Proper interpretation of renal biopsies requires examination
by light microscopy (LM), immunofluorescence (IF), and elec-
tron microscopy (EM). The tissue must be prepared and fixed in
the proper solutions; preparation of the tissue is relatively
simple, and the solutions are inexpensive and stable [45, 46]. If
complete examination (LM, IF, and EM) cannot be performed
at the hospital where the biopsy is obtained, the tissue should
be processed and submitted to a laboratory where the appro-
priate evaluations can be performed.
When the tissue is to be submitted to another pathologist, the
sample for electron microscopy should be divided into smaller
(1 mm) cubes and placed into Trump's fixative [45]; the tissue
for immunofluorescence should be cut into 2—4 mm cubes and
immediately "snap-frozen" in a precooled (—20°C) solution of
either isopentane, dry ice and acetone, or freon, and stored at
—70°C; if the specimen cannot be snap-frozen, it can be stored
in Michael's medium [46] for as long as one month. The
remaining tissue for light microscopy can be placed in any of a
number of common fixatives; we currently use Van der Grill's
[46]. On rare occasions, when the biopsy procedure can no
longer be continued, fewer than 5 to 10 glomeruli are obtained.
In this situation, the nephrologist must indicate the most likely
clinical diagnosis to the pathologist, so the specimen can be
processed in the most efficient manner.
Complications
Hematuria is the most common complication of percutaneous
biopsy [19]. Microscopic hematuria occurs in virtually all
patients, whereas gross hematuria occurs in 5% to 9%. The
presence of uncontrolled hypertension or uremia increases the
incidence of hematuria twofold [47]. Hematuria usually re-
solves spontaneously within 2 days, but in approximately 0.5%
of patients, hematuria persists for 2 to 3 weeks [21]. Occasion-
ally, gross hematuria first occurs several days after the biopsy,
but it too usually resolves within a few days with rest [19].
Transfusions are necessary in 0.1% to 3.0% of patients [19, 21,
23, 48]. Surgery for persistent or massive bleeding is required in
less than 0.2% of patients [19, 21].
Perinephric hematomas are common. If computerized tomog-
raphy is carried out one day after the biopsy procedure,
perinephric hematomas are detected in 57% to 85% of the
patients [49—51]. Most of these hematomas are clinically silent,
although occasionally an otherwise unexplained fall in hemato-
crit is observed [13, 21, 47]. Approximately 1% to 2% of
patients bleed sufficiently to develop hypotension, a fall in the
hematocrit, and a flank mass. Rarely, the onset of hemorrhage
is delayed for as long as 2 months [19, 52]. Hematomas usually
resolve within 3 months; they rarely become secondarily in-
fected and rarely require treatment with parenteral antibiotics
and surgical drainage [53].
Arteriovenous fistulas are also common; by arteriography
they can be demonstrated in as many as 15% to 18% of patients
[54—57]. Such lesions usually are clinically silent, and more than
95% resolve spontaneously within 2 years [54]. In rare in-
stances, surgical correction of the fistula is required because of
severe hypertension, persistent hematuria, congestive heart
failure, or hydronephrosis [56—59]. Post-biopsy aneurysms oc-
cur in less than 1% of patients [19, 54, 60, 61]. Infections are
unusual except in the presence of active pyelonephritis. Of 65
patients with pyelonephritis prior to renal biopsy, 7 developed
fever after the biopsy, and 4 of these patients developed
bacteremia [62]. There are many less common complications of
renal biopsy, including ileus; lacerations of the liver, spleen,
pancreas, intestine, gallbladder, and subcostal or visceral arter-
ies; puncture of the renal pelvis leading to urinoma; dislodged
renal stones; pancreatitis; pneumothorax; and dispersion of
carcinoma [19, 20, 45, 63—681.
As I indicated previously, the risk of nephrectomy is between
1/2000 to 1/5000 following renal biopsy. The risk of surgery for
nephrectomy or to repair a laceration due to biopsy is approx-
imately 1/500 to 1/1000 [19, 21, 47, 48, 63]. The risk of death
associated with surgery is related to the general health of the
patient.
Indications
Ideally, the information derived from a renal biopsy should
identify a specific diagnosis, accurately reflect the extent of
disease activity, and provide the basis for a decision about
specific therapy that could not otherwise be made. Unfortu-
nately, the pathologic findings often are not specific, and a
definitive diagnosis cannot always be made. Furthermore,
although the extremes of disease activity can be defined accu-
rately from the biopsy, the presence of either severe or minimal
disease usually can be predicted from the patient's clinical
features just as effectively. Between these extremes, structural-
functional correlations are poorly defined, and as a conse-
quence there often is considerable difference of opinion about
the clinical significance of intermediate levels of pathologic
activity. Thus, the prognosis and/or likelihood of response to
therapy cannot always be predicted with confidence. These
considerations complicate both the use of renal biopsy in
clinical practice, and its application to clinical research.
moderate >20
'50
severe >50
80 100
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An important consideration when performing a renal biopsy
is how the information will be utilized. Does identification of the
type of renal disease and estimation of severity influence the
diagnosis, prognosis, or therapy? Is tne information derived
from renal biopsy useful in patient management? Is the utility of
the information greater than that which can be derived from
clinical features alone or from other, less risky tests? Unfortu-
nately few studies of renal biopsy adequately address these
questions.
Paone and Meyer retrospectively examined 100 consecutive
renal biopsies to determine whether physicians' judgments
regarding treatment were altered by the biopsy results [69].
Although a definite or probable diagnosis was ascertained by
biopsy in 77% of patients, therapy was altered in only 19%.
None of the patients with acute or chronic renal insufficiency or
with hematuna as the indication for biopsy had an alteration of
treatment; changes in therapy were confined to the patients
with proteinuria. Similarly, Cohen and colleagues [70] and
Turner and coworkers [71] analyzed the influence of renal
biopsy on physicians' judgments regarding diagnosis, progno-
sis, and treatment in patients with diverse types of renal
disease. These two groups reported that changes in judgment
occurred predominantly in patients with heavy proteinuria or
systemic disease. Whiting-O'Keefe et al retrospectively ana-
lyzed the case histories of 30 patients who underwent renal
biopsy for severe lupus nephritis [72, 73]. Knowledge of the
biopsy result did not improve the accuracy of the physicians'
prognosis, including prediction of renal insufficiency or renal
failure, worsening proteinuria, or prescription of more aggres-
sive immunosuppressive therapy.
These studies have several shortcomings. Most important is
that they measure only physicians' judgments regarding the
type and severity of renal disease, not the outcomes of the
decisions they make regarding treatment. As demonstrated by
the results of decision analysis on the necessity of renal biopsy
for idiopathic nephrotic syndrome [74—76], differences in phy-
sicians' judgments do not necessarily translate into differences
in patients' survival or quality of life. Without data on out-
comes, including survival, development of renal failure, and
complications from treatment, conclusions based on physi-
cians' judgments alone must be considered of limited value.
In summary, there are no absolute indications for renal
biopsy. Nevertheless, virtually all nephrologists agree that the
information derived from the renal biopsy does have utility. In
the following discussion I will elaborate on my reasoned opin-
ions about the indications and the utility for renal biopsy in
various clinical presentations of renal disease. To do so I will
first consider the role of the biopsy in determining the type of
renal disease in the major renal syndromes and then consider
the studies that have attempted to assess the severity of renal
diseases as a guide to prognosis and therapy.
Acute renal failure. In most patients with acute renal failure,
the cause and type of renal disease can be determined without
a renal biopsy; obstruction, reduced renal perfusion, acute
tubular necrosis, and systemic diseases associated with acute
glomerulonephritis are usually evident from clinical, serologic,
renal ultrasound, and urine sediment examinations. In a rela-
tively small number of patients, however, a clear diagnosis
cannot be made from evaluation of clinical findings alone. The
most difficult diagnostic problems arise in circumstances in
which it is difficult to determine the type of renal disease from
the urine sediment. For example, if the urine sediment exami-
nation reveals red blood cells, renal tubular cells, and granular
casts but no red blood cell casts, reasonable possibilities to
explain the acute renal failure include a proliferative glomeru-
lonephritis, an inflammatory tubulointerstitial disease, a disease
of renal arterioles, or a combination of diseases. If the urine
sediment examination reveals only mild abnormalities, the
possibilities would include acute or chronic tubular injury or a
disease of large or medium-sized renal vessels. Ganeval et al
reported results of biopsies from 95 patients in whom acute
renal insufficiency did not appear to be due to volume depletion,
urinary tract obstruction, or acute tubular necrosis [77]. Gb-
merulonephritis occurred in 34% of their patients, interstitial
nephritis in 13%, vascular lesions in 16%, and a variety of
lesions in the remainder. Beaufils, Richet, and colleagues
reported on 218 biopsies from hospitalized patients with acute
renal insufficiency [78—80]. The patients did not have clinical
features of volume depletion, urinary tract obstruction, or acute
tubular necrosis. Glomerulonephritis was present in 24%, acute
interstitial nephritis in 14%, vascular lesions in 30%, and acute
tubular necrosis in 32%.
A renal biopsy may be required to determine the type and
extent of severity of disease in patients with acute renal failure,
and this information dictates therapy. In this regard, the results
of the renal biopsy in Patient 3 were very helpful, because they
obviated the need for further therapy, and they were predictive
of a good prognosis. Given these considerations, I recommend
prompt renal biopsy in patients with acute renal failure, in
whom the diagnosis cannot be made by routine clinical and
laboratory data.
Chronic renal failure. By contrast with acute renal failure, it
is frequently difficult to determine the cause and type of chronic
renal disease on the basis of clinical criteria alone. Kropp et al
reported the renal pathology on 29 consecutive patients who
underwent renal biopsy and on 17 consecutive patients sub-
jected to nephrectomy in preparation for renal transplantation
[30]. The clinical diagnosis was confirmed in 48%, a different
diagnosis was made in 43%, and no definitive diagnosis could be
made in 9%. Similar observations have been made more re-
cently by others [20, 22, 69]. Rarely, an unsuspected diagnosis
(such as oxalosis) can influence further clinical management
[46]. As I said previously, if both kidneys are small, the risk of
renal biopsy is increased (see previous discussion). Because it
is unlikely that assessment of either the type or severity of renal
disease will alter prognosis, therapy, or patients' outcomes, I
believe that renal biopsy usually is not warranted in this
circumstance.
Asymptomatic hematuria. Renal biopsy is abnormal in ap-
proximately 75% of patients with isolated hematuria (that is,
patients with no proteinuria, no other abnormalities of the
urinary sediment, normal renal function, and no structural
abnormalities of the urinary tract) [81, 82]. In such patients, IgA
nephropathy is the most common lesion, occurring in approxi-
mately 50% of patients [81]. Less frequent findings include
hereditary nephritis and other abnormalities of glomerular
basement membrane, isolated deposits of C3 in vessel walls,
and tubulointerstitial diseases [81—86]. Remarkably, 25% of
patients have normal biopsies [81, 82].
In the absence of proteinuria, decreased renal function, a
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family history of renal disease, or structural abnormalities of
the urinary tract, hematuria is likely due to mild glomerular
abnormalities. The likelihood of a renal biopsy elucidating the
source of hematuria is high, but the results are not likely to
affect therapy. A renal biopsy should be performed only if
defining the source of hematuria is necessary to obviate further
expensive or hazardous evaluations, to define the therapeutic
approach (including giving no therapy), or to reassure the
patient. The first patient presented today exemplifies a circum-
stance in which the information was useful in determining
whether the individual was a suitable kidney donor.
Asymptomatic proteinuria. Few studies are available on the
usefulness of renal biopsy in patients with mild to moderate
proteinuna (0.5 to 2.0 glday). In a series in Singapore of more
than 68,000 asymptomatic military recruits without a history of
hypertension or renal disease, less than 1% had persistent
proteinuria as the only urinary abnormality [871. Of 45 patients
in whom a renal biopsy was performed, the most common
lesion was focal glomerular sclerosis, which occurred in 33
patients. None of the lesions identified was considered serious
enough to require specific therapy, and the clinical significance
of these lesions remains uncertain. Although glomerular lesions
other than focal sclerosis that typically are associated with
nephrotic syndrome were not seen in this study, other studies
have documented that, with the exception of minimal-change
disease, all glomerular diseases can cause mild to moderate
proteinuria as their only manifestation [88, 89]. Tubulointersti-
tial diseases also can cause mild to moderate proteinuria, but
renal biopsy generally is not useful in identifying a specific
cause. Most often the biopsy reveals nonspecific findings such
as inflammation and fibrosis. Occasionally, infiltration of the
interstitium with eosinophils, deposition of immune complexes,
or immunoglobulins in tubules suggests a specific diagnosis
[90—961.
In summary, renal biopsy in patients with asymptomatic
proteinuria usually identifies a specific morphologic type of
glomerular disease. Treatment for idiopathic glomerular dis-
eases with non-nephrotic-range proteinuria is not well estab-
lished, however; hence the information is unlikely to affect the
therapeutic approach. Furthermore, if proteinuria is tubular in
origin or represents overproduction proteinuria, renal biopsy
generally is not helpful in making a specific diagnosis. The basis
for deciding whether to perform a biopsy in these patients
therefore is similar to that in patients with asymptomatic
hematuria.
Nephritic syndrome. Few studies have been published re-
garding the diagnostic utility of renal biopsy in patients with the
nephritic syndrome (as defined by the presence of hematuria,
proteinuria, and red blood cell casts). Because of substantial
overlap in pathologic features among various glomerulonephrit-
ides secondary to a systemic disease, the diagnosis of a specific
disease cannot always be determined by renal biopsy alone [97].
The cause of secondary glomerular diseases frequently can be
identified from the patient's clinical attributes without a renal
biopsy [98]. Nevertheless, when the cause of glomerular dis-
ease is not known, the information provided by renal biopsy can
be essential for making the diagnosis. If the cause is known, the
renal biopsy still can be useful in estimating the severity of the
disease.
In patients with primary glomerular disorders, the renal
biopsy provides information regarding the presence and extent
of inflammation and immune deposits. This information is
especially important for rapid diagnosis and initiation of therapy
in patients with glomerulonephritis and rapidly progressive
renal insufficiency. As a possible alternative to renal biopsy,
serologic tests have been proposed to distinguish among pa-
tients with linear, granular, or no immune deposits. The sensi-
tivity and specificity of serum antibodies to glomerular base-
ment membrane are each greater than 90% [99, 100], but the test
is available in only a few specialized laboratories. Anti-neutro-
phil cytoplasmic antibodies (ANCA) are highly specific for
patients with active Wegener's granulomatosus (>98% speci-
ficity by either indirect immunofluorescence or ELISA); how-
ever, the sensitivity varies with disease activity [101—1051. With
active systemic disease, the sensitivity is 93% to 96%; with
active regional disease, the sensitivity is only 60% to 67%, and
with inactive disease it is further reduced to 32% to 40%
[102—105]. False-positive results can occur in patients with
systemic lupus, but these can be distinguished from true posi-
tives by indirect immunofluorescence [1031. Less information is
available regarding ANCA in patients with necrotizing and
cresentic glomerulonephritis without systemic manifestations of
vasculitis. In these patients, the presence of ANCA has varied
from 0% to 75% of patients with active disease [102, 103, 1051.
In my opinion, the initial approach to the diagnosis of acute
glomerulonephritis is based on the patient's clinical and sero-
logic findings. I reserve renal biopsy for patients in whom these
findings do not identify a specific systemic disease. Because
accurate and prompt diagnosis is essential in selecting the type
of treatment in patients with the nephritic syndrome and rapidly
progressive renal insufficiency, I regard renal biopsy as the
definitive diagnostic test in this setting.
In most patients with systemic lupus erythematosus, I think
initial decisions regarding immunosuppressive therapy can and
should be based on an assessment of the severity of the disease,
as reflected in the urinalysis, an estimation of GFR, and
measurements of urinary protein excretion. In patients in whom
the severity of glomerular involvement, and hence the likeli-
hood of a response to treatment, cannot be ascertained from
these findings alone, renal biopsy can be helpful in determining
the need for initial immunosuppressive therapy.
Nephrotic syndrome. Routine clinical and serologic examina-
tion of patients with nephrotic syndrome usually allows the
physician to determine whether a systemic illness is present
[106]. In patients with primary (idiopathic) nephrotic syndrome,
however, the clinical features overlap to a great extent. Al-
though the use of multiple laboratory tests enhances the prob-
ability of distinguishing inflammatory from noninflammatory
lesions [107], it is not possible to predict the glomerular
pathology with confidence. Thus renal biopsy is the only
method for determining the type of renal disease in patients
whose clinical features do not clearly reveal a cause. Most
physicians assume that if an adequate specimen is obtained, the
pathologic features will either be pathognomonic for a systemic
disease or will be typical of one of four well-described primary
renal diseases: membranous nephropathy, minimal-change dis-
ease, focal and segmental glomerular sclerosis, or membrano-
proliferative glomerulonephritis (MPGN). In two series of
adults with nephrotic syndrome, however, as many as 20% of
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patients had proliferative glomerulonephritis or other morpho-
logic changes of uncertain classification [69, 107].
The decision of whether to use biopsy-guided therapy or
empiric treatment with high-dose, alternate-day steroids in all
patients with idiopathic nephrotic syndrome has been previ-
ously addressed in this Forum and elsewhere [74—76]. These
analyses were based on the assumption that high-dose, alter-
nate-day steroid therapy is the optimal treatment for idiopathic
membranous nephropathy and minimal-change disease, and the
model encompassed only patients with serum creatinine con-
centrations less than 1.5 mg/dl. These studies concluded that
both empiric therapy and biopsy-guided therapy are equally
effective and appropriate strategies. Thus, in my opinion, the
approach selected should be based on individual patient con-
siderations. To the extent that the physician believes that
Ponticelli's combination therapy approach of steroids and chlo-
rambL'cil [108] is more appropriate for patients with idiopathic
membranous nephropathy, then biopsy-guided therapy might
prove more appropriate. In clinical practice, I discuss these
issues with the patient, and we jointly decide the diagnostic and
therapeutic course. In most of my patients, the approach
utilized is biopsy-guided therapy.
Severity of disease. Accurate assessment of the severity of
disease is essential for determining both the extent of disease
activity and the probability that the disease will respond to
specific therapy. These considerations are especially important
when recommending potentially toxic treatments and for strat-
ification of patients in clinical trials. Accurate histologic evalu-
ation of renal biopsy specimens should identify those patients
with a poor prognosis. Ideally, the results of such histologic
evaluation also should serve as end points in clinical trials, so
the effect of therapy can be assessed prior to the development
of end-stage renal failure. Many indices have been derived, but
considerable disagreement exists regarding their value. In re-
cent studies, attempts have been made to develop reproducible
quantitative measures of disease activity and reversibility. Such
indices are intended to enhance clinical decision-making.
For such an index to have clinical utility, the severity of a
histologic lesion would have to correlate both with the severity
of functional alterations and with the patient's prognosis. Sur-
prisingly, even in patients with chronic glomerular disease, the
degree of renal functional impairment correlates better with the
extent of tubulointerstitial and vascular damage than with the
extent of glomerular damage. Redson, Sloper, and de Wardener
found a significant correlation between tubular atrophy and
creatinine clearance in patients with idiopathic and chronic
glomerular disease (nephritis or nephritic syndrome) [109].
Striker and colleagues evaluated structural-functional correla-
tions in patients with diverse renal diseases, including acute and
chronic glomerulonephritis, interstitial nephritis, and nephro-
sclerosis [110, 111]. They found a significant correlation be-
tween total interstitial and tubular damage and either renal
plasma flow or GFR, regardless of the underlying disease
process. Both interstitial fibrosis and inflammatory cell infiltra-
tion correlated with GFR, but interstitial edema did not. The
extent of vascular disease correlated reasonably well with renal
plasma flow. By contrast, a statistically significant relationship
between either renal plasma flow or GFR and the extent of
glomerular disease was not found. In patients with acute
proliferative glomerulonephritis, however, Parrish and cowork-
ers observed that glomerular cellularity correlated with inulin
clearance [112].
The relationship between renal structure and function has
been studied more recently in patients with diabetes mellitus,
membranous nephropathy, hypertension, and systemic lupus
erythematosus. In diabetes, Mauer, Steffes, and coworkers
measured mesangial volume and capillary surface area within
glomeruli and total glomerular volume by tracing glomeruli onto
digitizing tablets [113—116] and used a point grid system to
determine total and fractional volumes. They found that both
increased fractional mesangial volume per glomerulus and
diminished capillary filtration surface per glomerulus were
strongly associated with proteinuria, decreased GFR, and hy-
pertension [117]. Notably, microalbuminuria did not correlate
with these glomerular structural measurements, and glomerular
lesions were present in patients with normal urinary albumin
excretion rates. More recently, they used these morphologic
assessments to compare patients who received pancreatic
transplants following successful renal transplantation with dia-
betic patients who only received renal transplants [118]. Al-
though the creatinine clearances of both groups were similar,
mesangial volume and glomerular volume increased signifi-
cantly in the diabetics who had received only renal transplants.
In membranous nephropathy, proteinuria can persist despite
steroid and/or immunosuppressive therapy [119—123]. Repeated
morphologic analyses of biopsy specimens indicate that in
many patients, persistence of proteinuria is unassociated with
active immune deposit formation [124, 1251. To the extent that
effective treatment is developed to prevent immune deposit
formation, the biopsy could be helpful in identifying such
occurrences, and potentially toxic therapy could be withheld
during periods when immune deposits are not forming. In a
separate study of patients with membranous nephropathy,
Shemesh et al observed that both decreased circumferential
length of the glomerular capillary loops and reduction in the
number of filtration slits per unit of capillary loop length
correlated with the extent of proteinuria [126]. Similar morpho-
metric studies in patients with hypertension demonstrated that
intimal thickening and arteriolar hyaline changes in small ves-
sels correlated with the level and duration of hypertension
[127]. Richardson and coworkers recently examined the rela-
tionship between glomerular structure and function by compar-
ing conventional histopathology (light and electron microscopy)
with hemodynamic measurements (including calculation of KF)
in glomeruli isolated from the biopsies of patients with renal
diseases of diverse cause [128]. The KF correlated directly with
increasing glomerular size, glomerular hypercellularity, glomer-
ular capillary damage (scored semi-quantitatively), and urinary
protein excretion, and correlated inversely with percentage of
senescent glomeruli and epithelial foot process widening. They
found no correlation, however, between KF and serum creati-
nine.
Whether the information derived from renal biopsy adds
importantly to the assessment of the severity of renal disease
has been studied extensively in systemic lupus erythematosus
[73, 74, 129—141]. The extent of cellular proliferation and
capillary wall thickening of the glomerulus is the basis of the
World Health Organization (WHO) histologic classification
system. The WHO classification correlates histologic findings
with prognosis [89], but this classification is no more predictive
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Fig. 5. Representative digitized tracings of the outline of 2 glomerular
cross-sections. The upper tracing (A) is from a healthy control, the
lower (B) from a patient with active diffuse proliferative lupus nephritis.
Shaded areas depict patent capillary lumina, and dots the nuclei of
endocapillary cells. (From Ref. 146.)
of prognosis than are clinical features alone. In a retrospective
analysis of biopsy specimens from patients with acute lupus
nephritis, investigators at the U.S. National Institutes of Health
and the Walter Reed Army Medical Center examined the level
of histologic activity and chronicity in renal biopsies at study
entry, and then they correlated the histologic data with progres-
sion to end-stage renal failure [129, 140—143]. Semiquantitative
scores were assigned on the basis of glomerular and tubular
abnormalities. An activity index (a scale of 0 to 24) was based
on attributes of glomerular structure (including cellular prolif-
eration, fibrinoid necrosis, cellular crescents, hyaline thrombi,
and leukocyte infiltration) and tubulointerstial abnormalities
(including mononuclear cell infiltration). A chronicity index (a
scale of 0 to 12) also was determined from glomerular and
interstitial parameters (based especially on the extent of fibrosis
and tubular atrophy). Patients with a chronicity index of  1
had a significantly greater likelihood of developing renal failure
than did those with a chronicity index of less than 1 [140—143],
and patients with a chronicity index  4 had the worst progno-
sis. Patients with an activity index of  12 had a significantly
worse prognosis than did patients with an activity index of less
than 12, but the chronicity index was a better predictor of
outcome than was the activity index. Similar findings have been
reported in children with severe lupus nephritis [144]. The
results of a recent multicenter treatment trial of patients with
severe lupus nephritis raise questions about these conclusions,
however [145]. In this latter study, patients were retrospec-
tively divided into groups after completion of the study accord-
ing to the presence or absence of adverse outcome (death, renal
failure, 40% increase in serum creatinine). Neither the activity
index nor the chronicity index at study entry distinguished
patients who ultimately had a poor outcome.
These differences highlight some of the major difficulties
underlying the use of renal biopsy in clinical trials. Although
agreement is universal that knowing the extent of histologic
activity is essential to randomizing patients to treatment groups
in clinical studies of lupus nephritis, the histologic parameters
that determine outcome are not fully recognized. As I indicated
previously, distinctions that rely on small differences in a given
parameter (such as a single cutoff value for the chronicity index)
may have little meaning because a large overlap exists between
patient groups. Furthermore, conclusions often are based on
retrospective analysis alone. To validate the initial conclusions,
these markers should influence allocation of patients into treat-
ment groups in future studies. Other factors such as age,
duration of disease before treatment allocation, clinical activity
at study entry, and previous therapy also should be considered
concomitantly.
More recent studies of patients with lupus nephritis have
used more precise quantitative assessment of glomerular struc-
tural abnormalities for assessment of disease activity. Chagnac
et a! performed morphometric studies of glomerular capillary
area on serial biopsy specimens from patients with systemic
lupus erythematosus [146] (Fig. 5). They reported evidence of
progressive loss of glomerular capillary surface area with min-
imal or no change in proteinuria, GFR, or serum creatinine.
Whether quantitative assessment of severity of renal disease in
SLE from renal biopsy findings is more sensitive than assess-
ment from either clinical features alone or current histologic
evaluation, however, needs further investigation.
Questions and answers
DR. NJCOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): What
does adequacy of tissue mean for diagnosis of vascular disease
or interstitial disease?
DR. MADAI0: As with glomerular disease, "adequacy of
tissue" is highly dependent on both the extent and distribution
of the disease. With vasculitis the size and the freqency of
affected vessels are important factors. For patients with vascu-
litis involving primarily large and medium-size vessels, the
probability of making a definitive pathologic diagnosis from the
renal biopsy specimen is remote, because the biopsy needle is
intentionally directed away from these vessels. The probability
is higher for patients with vasculitis involving smaller vessels.
In practice, therefore, arteriography is more often the preferred
diagnostic test for patients suspected of having large or medi-
um-size vessel involvement. The diagnosis of Wegener's gran-
ulomatosis is usually made after histologic examination of
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tissue from the respiratory tract. Vasculitis involving small
vessels often can be diagnosed by renal biopsy; however, in
many cases, examination of more accessible tissue (such as
skin) usually provides the diagnosis.
For patients suspected of having vasculitis, I initially obtain 2
to 3 cores of tissue. If. after histologic examination of the tissue,
the specimen is inadequate, the patient can be biopsied again.
Although interstitial nephritis is almost always a focal process,
in my experience, 2 to 3 cores of tissue usually provide an
adequate quantity of interstitium to detect cellular infiltration.
In rare cases a second biopsy is necessary.
DR. MADIAS: How long would you wait in patients with acute
renal failure before you proceed to renal biopsy?
DR. MADAJO: At initial presentation, if prerenal azotemia and
urinary tract obstruction are excluded and the clinical factors
usually associated with acute tubular necrosis are absent, I
biopsy the patient immediately to determine whether a disease
amenable to therapy is present. The third case is a good
example of this situation. The biopsy also can provide useful
information in patients with prolonged renal failure presumed to
be secondary to acute tubular necrosis. Prognosis may be
ascertained (that is, the presence of cortical necrosis), and
occasionally an unsuspected disease is discovered.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): What else should
we be doing with the tissue obtained during the biopsy? Are
there new histologic techniques that we should be utilizing?
DR. ANGELO Ucci (Department of Pathology, New England
Medical Center): I think that many new techniques are still just
research tools; their clinical utility is doubtful currently. In an
academic center, I believe that immediate clinical benefit is not
our only consideration, however. Some specialized questions
can be answered using lymphocyte surface marker studies on
tissue from renal biopsy. We have had several patients with
acute renal failure whose renal biopsies revealed lymphomatous
involvement. We were able to determine the lymphocyte cell
type of these lymphomas with tissue procedures that are
available now. Quantitative measurements of fibril diameters
can be useful in distinguishing among various glomerular fibril-
loses, and some morphometric techniques might be applicable
to estimating the extent of disease. In-situ hybridization tech-
niques currently are proving useful in evaluating some tissue
biopsies for viral infections and other gene products. As such
techniques reveal information of diagnostic or therapeutic util-
ity, they can be rapidly used to more fully evaluate renal
biopsies.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): I would like to add two comments.
First, although renal biopsy is an exquisite tool for defining the
type and severity of renal disease, it lacks utility in many
clinical presentations because of the lack of therapies. If
adequate therapies were available for each type of disease that
can be defined by renal biopsy, then of course the biopsy would
have much greater utility. Clearly, as new therapies are discov-
ered, the utility of renal biopsy in different clinical presentations
must be re-analyzed. Second, the informational content of renal
biopsies is rarely judged by criteria that are relevant to the
patient. In most studies, the criteria by which the informational
content is judged are the physician's opinions regarding the
patient's diagnosis, treatment, and prognosis. However, the
major criteria that are relevant to the patient would be the effect
of biopsy on selection of therapy and the effect of therapy on
survival or quality of life. It also would be important to study
what value the patient places on information about prognosis
that does not directly affect therapy.
DR. MARY H. FOSTER (Division of Nephrology, New England
Medical Center): Could you comment on the variability in
interpretation of biopsy specimens by different pathologists?
DR. MADIA0: This is an important issue. Regarding the
pathologic diagnosis, I don't know of a study that addresses the
issue directly. In my opinion, it is crucial that the specimen be
processed and evaluated by an experienced renal pathologist,
and I have indicated in my discussion how this can be accom-
plished. Given this consideration, there is usually agreement on
the diagnosis. However, when a disagreement arises regarding
the severity of disease, the dispute can have important prog-
nostic and therapeutic implications. The pathologist therefore
must be as quantitative as possible in the description of the
histologic material. This should include reference to adequacy
of sample size and condition of the specimen, as well as the
extent of involvement. Ideally, in clinical practice, the nephrol-
ogist should review the slides and photographs with the pathol-
ogist. For clinical trials, it is important that each specimen be
analyzed in a similar manner, specific pathologic parameters be
defined both for entry criteria and study end points, and the
specimens be reexamined by a committee of pathologists. I
refer you to the report of the Lupus Nephritis Collaborative
Study Group [147] for an outstanding example of this practice.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief,
New England Medical Center): Is the risk of biopsy increased
for patients with comorbid conditions?
DR. MADIAO: The probability of bleeding is not increased;
the risks associated with therapy for severe bleeding are higher,
however. This is because of the greater incidence of therapeutic
intervention and the increased risk associated with the inter-
vention. For example, patients with preexisting anemia and
congestive heart failure are more likely to receive blood trans-
fusions than are patients without these conditions. Another
example is the higher surgical mortality rate in ASA class-4
patients compared with class-2 patients. If the risk of surgical
intervention after a renal biopsy is the same for both groups
(less than 0.2%), the mortality risk increases from 6/1,000,000
for class-2 patients to 1.6/10,000 for class-4 patients. These
considerations should be discussed with the patient prior to the
biopsy.
DR. MADIAS: Are the risks of renal biopsy increased in
patients with amyloidosis?
DR. MADIAO: The risk of bleeding is not increased in these
patients, providing they have normal coagulation and bleeding
parameters prior to the procedure. However, biopsy of more
accessible tissue, such as skin or subcutaneous fat, may provide
the diagnosis and obviate the need for renal biopsy [148—151].
DR. DEMETRIOS V. VLAHAKOS (Nephrology Fellow, New
England Medical Center): Dr. Kassirer, in a state-of-the-art
lecture at the 1989 meeting of the American Society of Nephrol-
ogy, a distinguished nephrologist showed the title of your
Nephrology Forum, "Is renal biopsy necessary for optimal
management of the idiopathic nephrotic syndrome?" and an-
swered this rhetorical question "yes." His conclusion seems to
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be at variance with the studies that you, Dr. Levey, and Dr.
Pauker have published [74, 75]. Would you comment?
DR. KASSIRER: Unfortunately, the title was used out of
context. The talk was centered around research in renal dis-
ease, not around clinical practice. We have never strayed from
the notion that biopsies are warranted—indeed, mandatory—as
part of properly designed and executed clinical investigative
efforts. We have only argued that biopsies are not needed in the
routine care of patients outside such studies. Indeed, I made
this distinction quite forcefully in the discussion of the very
paper whose title was shown at the meeting. I wrote, "What are
the implications for the research efforts currently underway to
determine the optimal approach to INS? Even if a generic
analysis shows that the choice between biopsy and 'blind'
treatment is a toss-up for all patients with INS {Note: it did
[75]}, the conclusion that the biopsy-directed approach offers no
benefit over 'blind' treatment would be applicable only to
patients being treated by physicians not engaged in this re-
search. Research efforts to identify optimal therapeutic ap-
proaches must continue because more effective treatment reg-
imens will be devised through such efforts [74]."
Is renal biopsy necessary for optimal management of the
idiopathic nephrotic syndrome (my original title) ? No. Is renal
biopsy necessary for optimal study of the idiopathic nephrotic
sydrome? Yes.
Iconoclastic views are not always popular, but both the
structure of our analysis and the data we employed have
withstood the test of time. When solid data on the efficacy of
new therapeutic approaches for the various histologic forms of
INS become available, our decision-analysis model could
readily be used again to assess whether renal biopsy offers any
special benefit for patients not involved in clinical research
projects.
Reprint requests to Dr. M. Madaio, Renal Electrolyte Section,
Hospital of the University of Pennsylvania, 700 Clinical Research
Building, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA
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